10 results on '"Zakir Thomas"'
Search Results
2. Ten simple rules for cultivating open science and collaborative R&D.
- Author
-
Hassan Masum, Aarthi Rao, Benjamin M Good, Matthew H Todd, Aled M Edwards, Leslie Chan, Barry A Bunin, Andrew I Su, Zakir Thomas, and Philip E Bourne
- Subjects
Biology (General) ,QH301-705.5 - Published
- 2013
- Full Text
- View/download PDF
3. Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis.
- Author
-
Rohit Vashisht, Anupam Kumar Mondal, Akanksha Jain, Anup Shah, Priti Vishnoi, Priyanka Priyadarshini, Kausik Bhattacharyya, Harsha Rohira, Ashwini G Bhat, Anurag Passi, Keya Mukherjee, Kumari Sonal Choudhary, Vikas Kumar, Anshula Arora, Prabhakaran Munusamy, Ahalyaa Subramanian, Aparna Venkatachalam, S Gayathri, Sweety Raj, Vijaya Chitra, Kaveri Verma, Salman Zaheer, J Balaganesh, Malarvizhi Gurusamy, Mohammed Razeeth, Ilamathi Raja, Madhumohan Thandapani, Vishal Mevada, Raviraj Soni, Shruti Rana, Girish Muthagadhalli Ramanna, Swetha Raghavan, Sunil N Subramanya, Trupti Kholia, Rajesh Patel, Varsha Bhavnani, Lakavath Chiranjeevi, Soumi Sengupta, Pankaj Kumar Singh, Naresh Atray, Swati Gandhi, Tiruvayipati Suma Avasthi, Shefin Nisthar, Meenakshi Anurag, Pratibha Sharma, Yasha Hasija, Debasis Dash, Arun Sharma, Vinod Scaria, Zakir Thomas, OSDD Consortium, Nagasuma Chandra, Samir K Brahmachari, and Anshu Bhardwaj
- Subjects
Medicine ,Science - Abstract
A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding of Mtb biology. We attempt to bridge this gap by carrying out extensive re-annotation and constructing a systems level protein interaction map of Mtb with an objective of finding novel drug target candidates. Towards this, we synergized crowd sourcing and social networking methods through an initiative 'Connect to Decode' (C2D) to generate the first and largest manually curated interactome of Mtb termed 'interactome pathway' (IPW), encompassing a total of 1434 proteins connected through 2575 functional relationships. Interactions leading to gene regulation, signal transduction, metabolism, structural complex formation have been catalogued. In the process, we have functionally annotated 87% of the Mtb genome in context of gene products. We further combine IPW with STRING based network to report central proteins, which may be assessed as potential drug targets for development of drugs with least possible side effects. The fact that five of the 17 predicted drug targets are already experimentally validated either genetically or biochemically lends credence to our unique approach.
- Published
- 2012
- Full Text
- View/download PDF
4. An open source pharma roadmap
- Author
-
Matthew H. Todd, Manica Balasegaram, Jaykumar A. Menon, Els Torreele, Zakir Thomas, Piero Olliaro, Tomasz Sablinski, Peter Kolb, John Wilbanks, and John C. McKew
- Subjects
0301 basic medicine ,Bacterial Diseases ,Computer and Information Sciences ,Competitive Behavior ,Knowledge management ,Drug Research and Development ,Drug Industry ,Essay ,Economics ,Science Policy ,Organizations, Nonprofit ,MEDLINE ,lcsh:Medicine ,Social Sciences ,India ,Global Health ,Computer Software ,03 medical and health sciences ,0302 clinical medicine ,Open Science ,Drug Discovery ,Global health ,Medicine and Health Sciences ,Tuberculosis ,Humans ,Public and Occupational Health ,030212 general & internal medicine ,Pharmacology ,Consumer Advocacy ,business.industry ,Research ,lcsh:R ,General Medicine ,Open source software ,Models, Theoretical ,Tropical Diseases ,030104 developmental biology ,Open source ,Infectious Diseases ,Drug development ,Open Source Drug Discovery ,Pharmaceutical Preparations ,Competitive behavior ,business ,Finance ,Open Source Software - Abstract
In an Essay, Matthew Todd and colleagues discuss an open source approach to drug development.
- Published
- 2017
5. Can India lead the way in neglected diseases innovation?
- Author
-
Gautam Kumar Saha, Kappoori Madhavan Gopakumar, Nirmal Kumar Ganguly, and Zakir Thomas
- Subjects
Biomedical Research ,business.industry ,Health Policy ,MEDLINE ,India ,Neglected Diseases ,General Medicine ,030204 cardiovascular system & hematology ,Public relations ,Translational Research, Biomedical ,03 medical and health sciences ,0302 clinical medicine ,Lead (geology) ,Drug Development ,Political science ,Humans ,030212 general & internal medicine ,Diffusion of Innovation ,business ,Drug Approval ,Analysis ,Health policy - Abstract
Nirmal Kumar Ganguly and colleagues call for a comprehensive policy for neglected diseases research in India to foster innovation in drugs, diagnostics, and vaccines, critical for evolving needs of elimination programmes
- Published
- 2019
- Full Text
- View/download PDF
6. Common Heritage to Common Concern
- Author
-
Zakir Thomas
- Subjects
business.industry ,Environmental resource management ,Environmental ethics ,business ,Law - Published
- 2005
- Full Text
- View/download PDF
7. Agricultural Biotechnology and Proprietary Rights. Challenges and Policy Options
- Author
-
Zakir Thomas
- Subjects
Natural resource economics ,Business ,Agricultural biotechnology ,Law ,Agricultural economics - Published
- 2005
- Full Text
- View/download PDF
8. Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis
- Author
-
Swati Gandhi, Vishal Mevada, Varsha Bhavnani, Aparna Venkatachalam, Nagasuma Chandra, Anurag Passi, Gayathri S, Soumi Sengupta, Swetha Raghavan, Trupti Kholia, Anupam Kumar Mondal, Pankaj Kumar Singh, Samir K. Brahmachari, Debasis Dash, Tiruvayipati Suma Avasthi, Anup Shah, Girish Muthagadhalli Ramanna, Malarvizhi Gurusamy, Balaganesh J, Madhumohan Thandapani, Pratibha Sharma, Harsha Rohira, Arun Sharma, Anshula Arora, Prabhakaran Munusamy, Rohit Vashisht, Kumari Sonal Choudhary, Zakir Thomas, Keya Mukherjee, Ilamathi Raja, Raviraj Soni, Priti Vishnoi, Priyanka Priyadarshini, Shruti Rana, Ashwini G. Bhat, Vinod Scaria, Kaveri Verma, Rajesh Patel, Mohammed Razeeth, Ahalyaa Subramanian, Kausik Bhattacharyya, Salman Zaheer, Lakavath Chiranjeevi, Sweety Raj, Vijaya Chitra, Anshu Bhardwaj, Shefin Nisthar, Meenakshi Anurag, Vikas Kumar, Yasha Hasija, Naresh Atray, Akanksha Jain, Sunil N. Subramanya, and OSDD Consortium
- Subjects
Bacterial Diseases ,Drugs and Devices ,Drug Research and Development ,Proteome ,Science ,Gene regulatory network ,Genomics ,Context (language use) ,Computational biology ,Biology ,Genome ,Interactome ,Biochemistry ,Mycobacterium ,Drug Delivery Systems ,Bacterial Proteins ,Genome Analysis Tools ,ddc:570 ,Protein Interaction Mapping ,Drug Discovery ,Genetics ,Humans ,Tuberculosis ,Gene Regulatory Networks ,Protein Interactions ,Whole genome sequencing ,Multidisciplinary ,Drug discovery ,Macrophages ,Systems Biology ,Proteins ,Computational Biology ,Mycobacterium tuberculosis ,Infectious Diseases ,Host-Pathogen Interactions ,Crowdsourcing ,Medicine ,Gene Function ,Genome, Bacterial ,Signal Transduction ,Research Article - Abstract
A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding of Mtb biology. We attempt to bridge this gap by carrying out extensive re-annotation and constructing a systems level protein interaction map of Mtb with an objective of finding novel drug target candidates. Towards this, we synergized crowd sourcing and social networking methods through an initiative `Connect to Decode' (C2D) to generate the first and largest manually curated interactome of Mtb termed `3interactome pathway' (IPW), encompassing a total of 1434 proteins connected through 2575 functional relationships. Interactions leading to gene regulation, signal transduction, metabolism, structural complex formation have been catalogued. In the process, we have functionally annotated 87% of the Mtb genome in context of gene products. We further combine IPW with STRING based network to report central proteins, which may be assessed as potential drug targets for development of drugs with least possible side effects. The fact that five of the 17 predicted drug targets are already experimentally validated either genetically or biochemically lends credence to our unique approach.
- Published
- 2011
9. Collaborative Tools to Accelerate Neglected Disease Research: Open-Source Drug Discovery Model
- Author
-
Vinod Scaria, Samir K. Brahmachari, Zakir Thomas, Anshu Bhardwaj, and Santhosh Adayikkoth
- Subjects
World Wide Web ,Open source ,Drug discovery ,Computer science ,Neglected Disease ,Data science - Published
- 2011
- Full Text
- View/download PDF
10. Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development
- Author
-
Muthukurussi Varieth Raghunandanan, Nagasuma Chandra, Srinivasan Ramachandran, Jaijit Bhattacharya, Andrew M. Lynn, Bhupesh Taneja, Vinod Scaria, Jyoti Yadav, Anil Kumar, Zakir Thomas, Vikas Pandey, Debasis Dash, Samir K. Brahmachari, Amit Misra, Gajendra P. S. Raghava, Sulagna Banerjee, and Anshu Bhardwaj
- Subjects
Microbiology (medical) ,Knowledge management ,business.industry ,Drug discovery ,Immunology ,Industrial research ,Antitubercular Agents ,Information technology ,Developing country ,India ,Mycobacterium tuberculosis ,Microbiology ,Infectious Diseases ,Open source ,Drug development ,Drug Design ,Research Support as Topic ,Humans ,Immunologic Factors ,Tuberculosis ,Confidentiality ,Lower cost ,Cooperative Behavior ,business ,Tuberculosis Vaccines - Abstract
It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.